Larry Anderson, MD, PhD, Discusses CAR T-Cell Therapy For Multiple Myeloma at 2021 IMW


CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 18th International Myeloma Workshop to talk about how the emergence of CAR T-cell therapies in multiple myeloma affects multidisciplinary clinicians.

At the 18th Annual International Multiple Myeloma Workshop, CancerNetwork® spoke with Larry Anderson, MD, PhD, of UT Southwestern, about the real-world considerations of CAR T-cell therapy administration in patients with multiple myeloma. Anderson explained the advantage of having a multidisciplinary team of clinicians who are trained in managing patients on CAR T-cell therapy.


First, one thing to highlight is that CAR T-cell therapy, although it works very well, does have specific toxicities that one has to be experienced with to be able to give this therapy. Right now, it’s [administration is] limited to large referral centers like bone marrow transplant centers and academic medical centers that have expertise with stem cell and cell therapies. These products involve a lot of disciplines. We have social workers for these patients, and we have a lot of different team members helping to make sure this [treatment] goes smoothly.

For example, because of the risk of neurotoxicity and risk of seizures with any CAR T-cell product, these patients can’t drive for 2 months. They must have a caregiver who can bring them to appointments. They must have wallet cards to let providers know [to send] them somewhere else that if they have fevers or symptoms of cytokine release syndrome or neurotoxicity. [These cards] will have our contact information and let [providers] know that those patients need to get to our center as soon as possible. These patients generally will need to live within a couple hours of the medical center for the first month. It does impact a lot of their lifestyle, but I would say the biggest impact is after the first month, once these patients are off therapy for the first time in many years [or even] a decade, they enjoy not being on treatment for the coming years after the CAR T-cell infusion. They really enjoy the freedom that that brings.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Related Content